Advertisement
Organisation › Details
CureVac RNA Printer GmbH
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer®. The RNA Printer® is CureVac’s solution for integrated and automated manufacturing of GMP-grade RNA vaccines and therapeutics. The new entity is designed as a platform and services company, providing a dedicated operational environment to further develop and establish The RNA Printer® as a manufacturing end-to-end solution. This solution will include the main steps to manufacture mRNA vaccines or therapeutics. The platform is designed to facilitate broad access to mRNA technology and enable mRNA product developments, e.g. for rapid supply of new mRNA-based vaccines in pandemic situations as well as patient access to advanced and personalized mRNA-based therapies in oncology. The company will be led by Dr. Markus Bergmann, who joins CureVac RNA Printer GmbH as General Manager on March 1, 2022. *
Start | 2021-09-07 established (reorg) | |
Group | CureVac (Group) | |
Industry | RNA Printer™ (for LNP-formulated mRNA vaccine production) | |
Person | Bergmann, Markus (CureVac 202203– Managing Director CureVac RNA Printer GmbH before ZF Group + Rools Royce + McKinsey) | |
Region | Tübingen | |
Country | Germany | |
Street | 15 Friedrich-Miescher-Str. | |
City | 72076 Tübingen | |
Address record changed: 2022-04-25 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: CureVac N.V.. (3/1/22). "Press Release: CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer". Tübingen & Boston, MA. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for CureVac (Group)
- [1] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
- [2] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
- [3] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
- [4] CureVac N.V.. (9/28/23). "Press Release: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany". Tübingen & Boston, MA....
- [5] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....
- [6] LimmaTech Biologics AG. (7/20/23). "Press Release: LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth". Schlieren....
- [7] CureVac N.V.. (7/14/23). "Press Release: CureVac Announces Update to the Management Team". Tübingen & Boston, MA....
- [8] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....
- [9] CureVac N.V.. (2/8/23). "Press Release: CureVac Announces Pricing of Upsized Public Offering of Common Shares". Tübingen & Boston, MA....
- [10] CureVac N.V.. (2/6/23). "Press Release: CureVac Announces Proposed Public Offering of Common Shares". Tübingen & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top